Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Giovanna Cirnigliaro, Vera Battini, Michele Castiglioni, Marica Renne, Giulia Mosini, Stefania Cheli, Carla Carnovale & Bernardo Dell’Osso. (2024) Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults. Expert Review of Neurotherapeutics 24:4, pages 325-332.
Read now
Read now
Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal & John M Kane. (2023) The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric Disease and Treatment 19, pages 531-545.
Read now
Read now
Juan Antonio García-Carmona & Sofia Pappa. (2023) Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal. Drug, Healthcare and Patient Safety 15, pages 113-123.
Read now
Read now
Ibrahim Turkoz, Mehmet Daskiran, H Lynn Starr, Dean Najarian, Oliver Lopena, Camilo Obando, Alexander Keenan, Carmela Benson & Srihari Gopal. (2022) Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections. Neuropsychiatric Disease and Treatment 18, pages 1927-1937.
Read now
Read now
Articles from other publishers (4)
Ibrahim Turkoz, Mehmet Daskiran, Uzma Siddiqui, R Karl Knight, Karen L Johnston & Christoph U Correll. (2024) Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations. International Journal of Neuropsychopharmacology 27:2.
Crossref
Crossref
Dee Lin, Dominic Pilon, Laura Morrison, Aditi Shah, Marie-Hélène Lafeuille, Patrick Lefebvre & Carmela Benson. (2023) A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia. Drugs - Real World Outcomes 10:3, pages 471-480.
Crossref
Crossref
Hilary PhelpsDee LinAlex KeenanAditya RajuDanmeng HuangChih-Yuan ChengCarmela Benson. (2023) Budget impact of introducing once-every-6-months paliperidone palmitate in US health care plans. Journal of Managed Care & Specialty Pharmacy 29:3, pages 303-313.
Crossref
Crossref
Phoebe Wallman, Ivana Clark & David Taylor. (2022) Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort – A five-year mirror image study. Journal of Psychiatric Research 148, pages 131-136.
Crossref
Crossref